Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
AssigneeTherapeutic Human Polyclonals, Inc.
InventorRoland Buelow
Life of this patent
Estimating the term…
Abstract
The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or Igβ sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Igα and/or Igβ results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.
Claims6
An isolated B-cell from a transgenic rabbit whose genome comprises:
- (a) a transgene construct encoding a full-length, human Igα , subunit of SEQ ID NO:
- 1, under the control of a B-cell specific promoter/enhancer of CD79a;
- (b) a transgene construct encoding a full-length, human Igβ subunit of SEQ ID NO:
- 7, under the control of a B-cell specific promoter/enhancer of CD79b;
- and (c) a transgene construct encoding an unrearranged human immunoglobulin heavy chain locus, wherein the resultant transgene products, as a result of the simultaneous expression of the transgene constructs (a)-(c), combine to form a human B-cell receptor complex, such that human CD79a, human CD79b and human IgM are simultaneously present on the surface of said B-cell.
Dependencies are inferred from the claim text.